Remus PharmaceuticalsNSE:REMUS -1.04%61 PE Ratio (TTM) is 18.88 as of Jul. 12, 2026, which is 59% below its 10-year median of 46.49. GuruFocus rates NSE:REMUS with a GF Score™ of 61/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 87 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 62.07% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-12), Remus Pharmaceuticals's share price is
₹739.95.
Remus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹39.19. Therefore, Remus Pharmaceuticals's PE Ratio (TTM) for today is 18.88.
The historical rank and industry rank for Remus Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
NSE:REMUS'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 16.07 Med: 46.49 Max: 332.99
Current: 18.88
During the past 7 years, the highest PE Ratio (TTM) of Remus Pharmaceuticals was 332.99. The lowest was 16.07. And the median was 46.49.
NSE:REMUS's PE Ratio (TTM) is ranked worse than 62.07% of 87
companies
in the Medical Distribution industry
Industry Median: 15.5
vs NSE:REMUS: 18.88
During the past 7 years, Remus Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 199.30% per year. The lowest was 122.20% per year. And the median was 160.75% per year.
Remus Pharmaceuticals (NSE:REMUS) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Remus Pharmaceuticals PE Ratio (TTM) Related Terms
Remus Pharmaceuticals PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: PE Ratio (TTM) Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals PE Ratio (TTM) vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Remus Pharmaceuticals's Share Price of today is ₹739.95.
For company reported semi-annually, Remus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹39.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Remus Pharmaceuticals (NSE:REMUS) has a PE Ratio (TTM) of 18.88 as of Jul. 12, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Remus Pharmaceuticals and its competitors. This is 59% below median its historical median of 46.49. Over the past decade, Remus Pharmaceuticals' PE Ratio (TTM) has ranged from 16.07 to 332.99. According to the industry distribution chart, Remus Pharmaceuticals ranks #54 out of 87 companies in the Medical Distribution industry, placing it in the top 62.1%.
Is Remus Pharmaceuticals' PE Ratio (TTM) too high?
Remus Pharmaceuticals' current PE Ratio (TTM) of 18.88 is 59% below median its 10-year median of 46.49. Over the past 10 years, this metric has ranged from a low of 16.07 to a high of 332.99. The Medical Distribution industry median PE Ratio (TTM) is 15.50. Remus Pharmaceuticals' value of 18.88 is 21.8% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #54 out of 87 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' PE Ratio (TTM) compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #54 out of 87 companies for PE Ratio (TTM). This places Remus Pharmaceuticals in the lower half of its industry. The industry median PE Ratio (TTM) is 15.50. Remus Pharmaceuticals' value of 18.88 is 21.8% above this benchmark. Historically, Remus Pharmaceuticals' own PE Ratio (TTM) has ranged from 16.07 to 332.99 over the past decade. While the company's 10-year median is 46.49 vs. the industry median of 15.50, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Distribution company?
The median PE Ratio (TTM) among Medical Distribution companies is 15.50, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current PE Ratio (TTM) of 18.88 is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median PE Ratio (TTM) is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current PE Ratio (TTM) is 18.88, which is 59% below median its own 10-year median of 46.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹739.95 — trading 64.3% below its estimated fair value. The current PE Ratio (TTM) is 18.88, which is 59% below median its 10-year median of 46.49 and 21.8% above the Medical Distribution industry median of 15.50. Remus Pharmaceuticals' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current PE Ratio (TTM) is 18.88 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹739.95 is trading 64.3% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
PE Ratio (TTM): 18.88 (59% below median its 10-year median of 46.49)
GF Value™: ₹2,071.36 vs. price of ₹739.95 (64.3% below fair value)
Industry Position: 21.8% above the Medical Distribution median (#54 of 87)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
61GF Score
Get the complete analysis for NSE:REMUS
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
